Bank of America Says It Budgets About $250 Million a Year for GLP-1 Obesity Drugs for Employees

Bank of America is spending about $250 million a year on GLP-1 drugs, including obesity treatments such as Ozempic, to support employees’ health, CEO Brian Moynihan said, framing the program as “a good investment.” The remarks were reported by Yahoo Finance in a piece published August 7, 2026, describing the bank’s growing use of modern weight-loss medications as part of its workforce benefits.

GLP-1 drugs, also known as glucagon-like peptide-1 receptor agonists, have been adopted widely for type 2 diabetes and, in some cases, for obesity and weight management. In the context of employer-sponsored benefits, the key question is how such medications affect employee health outcomes, healthcare utilization, and day-to-day productivity.

According to the report, Bank of America allocates millions each year for access to these medications for employees, with Moynihan citing the “good investment” angle. The CEO’s comments linked the spending to workforce health and productivity rather than treating the medications solely as a clinical benefit with uncertain returns.

The company did not, in the reported account, break out detailed program design elements such as which specific GLP-1 products are covered beyond Ozempic, whether access is tied to medical criteria, or how coverage changes over time. It also did not provide figures by business unit, geography, or employee category in the cited reporting.

Nor did the account specify the financial mechanics of the benefits cost. Employers typically face a blend of pharmacy plan expenses, specialty drug procurement or reimbursement terms, and administrative costs, but the reported material did not lay out whether Bank of America fully bears the cost through its plan design, shares it with employees via premiums or copays, or negotiates pricing directly with pharmacy benefit managers.

This development fits a broader shift in corporate benefits in the United States, where GLP-1 adoption has spread from insurer and employer pilot programs into larger scale coverage questions. Companies have faced increasing scrutiny over whether these drugs are managed responsibly, how they are integrated into broader wellness programs, and how to contain costs while ensuring appropriate access.

Bank of America’s decision, as described in the report, suggests the bank views GLP-1 coverage as more than a passing trend, but the public details remain limited. Until additional specifics are disclosed, it is not possible to verify the share of total employee healthcare spend the GLP-1 program represents, nor to determine what measurable workforce outcomes the company expects to track.

What to watch next is whether Bank of America provides further transparency in future earnings materials, benefits updates, or investor communications, such as program scope, eligibility guidance, expected cost trends, and the metrics it uses to evaluate whether the “good investment” framing holds over time.